Focused On-demand Library for Lymphocyte antigen 75

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O60449

UPID:

LY75_HUMAN

Alternative names:

C-type lectin domain family 13 member B; DEC-205; gp200-MR6

Alternative UPACC:

O60449; O75913; Q53R46; Q53TF5; Q7Z575; Q7Z577

Background:

Lymphocyte antigen 75, also known as C-type lectin domain family 13 member B, DEC-205, and gp200-MR6, plays a crucial role in the immune system. It acts as an endocytic receptor, directing captured antigens from the extracellular space to a specialized antigen-processing compartment. This process is vital for the proper functioning of the immune response, as it facilitates the presentation of antigens to B-lymphocytes, albeit causing reduced proliferation of these cells.

Therapeutic significance:

Understanding the role of Lymphocyte antigen 75 could open doors to potential therapeutic strategies. Its involvement in antigen processing and presentation positions it as a key player in the development of vaccines and immunotherapies, offering new avenues for enhancing immune responses against pathogens and tumors.